Neoadjuvant pembrolizumab and chemotherapy in resectable clinical stage III non-small-cell lung cancer: a retrospective cohort study.

Guangyin Zhao,Hongyu Zhang,Fengkai Xu,Chunlai Lu,Qiaoliang Zhu,Francesco Grossi,Duilio Divisi,Teng Ma,Jie Gu,Di Ge

Translational lung cancer research（2023）

引用 1|浏览14

暂无评分

摘要

Neoadjuvant pembrolizumab plus chemotherapy could be considered reliable for clinical stage III NSCLC, but needs to be validated with more robust clinical trials.

查看译文

关键词

Non-small-cell lung cancer (NSCLC),complete pathological response (CPR),major pathological response (MPR),neoadjuvant therapy,treatment-related adverse event (trAE)

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要